Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Acetadote — Revenue

Other product segments

Kristalose
$3.12M-28.7%
Sancuso
$2.93M+29.8%
Vibativ
$2.12M-29.4%
Talicia
$1.92M—
Caldolor
$896.71K-34.7%
Other revenue
$168.85K-94.6%

Similar metrics at other companies

United Therapeutics logo
UTHRAdcirca — Total revenues
$2.9M-51.7%
Supernus Pharmaceuticals logo
SUPNAPOKYN — Total revenues
$7.73M-48.4%
Pfizer logo
PFEProduct — Revenue
$11.72B+3.7%
Bausch Health Companies logo
BHCProduct sales — Revenue
$2.5B+12.3%
AMP
AMPHPharmaceutical Products — Revenue
$171.17M+0.4%
Kiniksa Pharmaceuticals International, plc logo
KNSAPharmaceutical — Revenue
$214.27M+55.5%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's acetadote — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's acetadote — revenue?
Cumberland Pharmaceuticals (CPIX) reported acetadote — revenue of $51.98K in Q1 2026.
How has Cumberland Pharmaceuticals's acetadote — revenue changed year-over-year?
Cumberland Pharmaceuticals's acetadote — revenue decreased by 65.7% year-over-year, from $151.65K to $51.98K.
What is the long-term trend for Cumberland Pharmaceuticals's acetadote — revenue?
Over 3 years (2022 to 2025), Cumberland Pharmaceuticals's acetadote — revenue has grown at a 0.5% compound annual growth rate (CAGR), from $501.04K to $508.46K.
What does acetadote — revenue mean?
Represents the total gross sales generated from the specific pharmaceutical product line before any deductions for returns, allowances, or rebates. This metric serves as a primary indicator of market demand and the commercial success of the product within its targeted therapeutic category.